Khalil had no disclosures and no external study funding was noted. One co-investigator reported stock options in Allurion, ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

The origins of autoimmune diseases like it are often mysterious, and an immune system that sees the body it inhabits as an ...

With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...

Bristol Myers Squibb reported strong third-quarter financial results, notching an 18% jump in its growth portfolio.

Lawyers for AstraZeneca , Bristol Myers Squibb and Johnson & Johnson's Janssen on Wednesday urged a federal appeals court in ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

Sales of blood cancer drug Revlimid, which is now facing generic competition, dropped 11% to $1.41 billion in the quarter, ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has given ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

In a welcome move, Bristol Myers Squibb saw its Relative Strength Rating improve from 70 to 76 on Tuesday. Please watch the video at Investors.com - Stock Market Exposure: How To Make Incremental ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood ...